Literature DB >> 9120001

Regulation of polymorphonuclear cell activation by thrombopoietin.

M F Brizzi1, E Battaglia, A Rosso, P Strippoli, G Montrucchio, G Camussi, L Pegoraro.   

Abstract

Thrombopoietin (TPO) regulates early and late stages of platelet formation as well as platelet activation. TPO exerts its effects by binding to the receptor, encoded by the protooncogene c-mpl, that is expressed in a large number of cells of hematopoietic origin. In this study, we evaluated the expression of c-Mpl and the effects of TPO on human polymorphonuclear cells (PMN). We demonstrate that PMN express the TPO receptor c-Mpl and that TPO induces STAT1 tyrosine phosphorylation and the formation of a serum inducible element complex containing STAT1. The analysis of biological effects of TPO on PMN demonstrated that TPO, at concentrations of 1-10 ng/ml, primes the response of PMN to n-formyl-met-leu-phe (FMLP) by inducing an early oxidative burst. TPO-induced priming on FMLP-stimulated PMN was also detected on the tyrosine phosphorylation of a protein with a molecular mass of approximately 28 kD. Moreover, we demonstrated that TPO by itself was able to stimulate, at doses ranging from 0.05 to 10 ng/ml, early release and delayed synthesis of interleukin 8 (IL-8). Thus, our data indicate that, in addition to sustaining megakaryocytopoiesis, TPO may have an important role in regulating PMN activation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9120001      PMCID: PMC507977          DOI: 10.1172/JCI119320

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  IL-8 production by human polymorphonuclear leukocytes. The chemoattractant formyl-methionyl-leucyl-phenylalanine induces the gene expression and release of IL-8 through a pertussis toxin-sensitive pathway.

Authors:  M A Cassatella; F Bazzoni; M Ceska; I Ferro; M Baggiolini; G Berton
Journal:  J Immunol       Date:  1992-05-15       Impact factor: 5.422

2.  Cell-free activation of a DNA-binding protein by epidermal growth factor.

Authors:  H B Sadowski; M Z Gilman
Journal:  Nature       Date:  1993-03-04       Impact factor: 49.962

Review 3.  Neutrophil signal transduction and activation of the respiratory burst.

Authors:  M Thelen; B Dewald; M Baggiolini
Journal:  Physiol Rev       Date:  1993-10       Impact factor: 37.312

Review 4.  Cytokine signal transduction.

Authors:  T Kishimoto; T Taga; S Akira
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

5.  Modulation of PAF-induced leukocyte adherence and increased microvascular permeability.

Authors:  P Kubes; M Suzuki; D N Granger
Journal:  Am J Physiol       Date:  1990-11

6.  Selective inhibition of human neutrophil functional responsiveness by erbstatin, an inhibitor of tyrosine protein kinase.

Authors:  P H Naccache; C Gilbert; A C Caon; M Gaudry; C K Huang; V A Bonak; K Umezawa; S R McColl
Journal:  Blood       Date:  1990-11-15       Impact factor: 22.113

7.  Involvement of tyrosine kinases in the activation of human peripheral blood neutrophils by granulocyte-macrophage colony-stimulating factor.

Authors:  S R McColl; J F DiPersio; A C Caon; P Ho; P H Naccache
Journal:  Blood       Date:  1991-10-01       Impact factor: 22.113

8.  Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily.

Authors:  I Vigon; J P Mornon; L Cocault; M T Mitjavila; P Tambourin; S Gisselbrecht; M Souyri
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

9.  Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis.

Authors:  N Methia; F Louache; W Vainchenker; F Wendling
Journal:  Blood       Date:  1993-09-01       Impact factor: 22.113

10.  Expression of the c-mpl proto-oncogene in human hematologic malignancies.

Authors:  I Vigon; F Dreyfus; J Melle; F Viguié; V Ribrag; L Cocault; M Souyri; S Gisselbrecht
Journal:  Blood       Date:  1993-08-01       Impact factor: 22.113

View more
  4 in total

1.  Blockade of Thrombopoietin Reduces Organ Damage in Experimental Endotoxemia and Polymicrobial Sepsis.

Authors:  Alessandra Cuccurullo; Elisabetta Greco; Enrico Lupia; Paolo De Giuli; Ornella Bosco; Erica Martin-Conte; Tiziana Spatola; Emilia Turco; Giuseppe Montrucchio
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

2.  Thrombopoietin Contributes to Enhanced Platelet Activation in Patients with Type 1 Diabetes Mellitus.

Authors:  Ornella Bosco; Barbara Vizio; Gabriella Gruden; Martina Schiavello; Bartolomeo Lorenzati; Paolo Cavallo-Perin; Isabella Russo; Giuseppe Montrucchio; Enrico Lupia
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

Review 3.  Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseases.

Authors:  Enrico Lupia; Alberto Goffi; Ornella Bosco; Giuseppe Montrucchio
Journal:  Mediators Inflamm       Date:  2012-04-05       Impact factor: 4.711

Review 4.  Platelets and Multi-Organ Failure in Sepsis.

Authors:  Elisabetta Greco; Enrico Lupia; Ornella Bosco; Barbara Vizio; Giuseppe Montrucchio
Journal:  Int J Mol Sci       Date:  2017-10-20       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.